In our lifetime, 1 in 2 men and 1 in 3 women will be diagnosed with cancer.  I joined the Swim Across America community so that, together, we can change that.  If you are able, please support me, or my team, Team Rogel, by making a gift.  The  researchers we are funding are in our community and are the next generation of cancer pioneers.  

As a lab manager at the Rogel Cancer Center at Michigan Medicine, I have seen the difference that early stage funding, such as the grants awarded by Swim Across America, can make.  Swim Across America funding fills a critical need by allowing researchers to conduct pilot experiments to collect preliminary data that is needed to secure a major grant from the NIH or from industry, and enables them to work towards clinical trials that make a real difference for patients.

Swim Across America grants have played a major role in clinically developing FDA-approved immunotherapy treatments ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), and atezolizumab (TECENTRIQ).  In a study published in the New England Journal of Medicine this June, 12 patients completed a phase 2 clinical trial for advanced rectal cancer and showed a 100% clinical complete response to dostarlimab, an immunotherapy treatment produced by GlaxoSmithKline. The clinical trial was conducted at Memorial Sloan Kettering with early-stage grant funding from Swim Across America.  Read more about this exciting research at the link below:

 https://www.eurekalert.org/news-releases/955423

Thank you for helping make an impact in the fight to find a cure!